The 2015 recommendations for PsA treatment highlight the importance of managing comorbidities and a patient-centered treatment approach.
Identifying the difference between Lyme arthritis or another inflammatory arthritis can be tricky. Here are key signs that your patient may have a systemic inflammatory arthritis rather than Lyme arthritis.
When a patient presents with a history of Lyme disease and joint pain, refractory Lyme arthritis seems reasonable, but then, this study warns of systemic arthritis after a Lyme disease infection.
When methotrexate fails in rheumatoid arthritis, the next-line treatment is usually a TNF-α inhibitor. But if this treatment fails as well, what's next?
Low bone mineral density and osteoporosis are well-known comorbidities with systemic lupus erythematosus. In this slideshow, we highlight six of the most common risk factors for low bone mineral density in SLE.
Age and cumulative glucocorticoid exposure are key risk factors for low bone mineral density in systemic lupus erythematosus.
For high risk patients with systemic lupus erythematosus, teriparatide and denosumab may be an option for patients who have failed bisphosphonates. Here are some key points you need to know.
Bone loss could affect as many as 31 percent of SLE patients. This article sums up the treatment options from first-line bisphosphonate recommendations to emerging treatments like abaloparatide.
All patients about to undergo surgery should be preoperatively evaluated for fall history, a study shows.
Q&A: Two experts discuss proposals for formal CVD risk calculators in RA and the need for long-term research to validate them.